Coronary Artery Disease: Current Evidence and Future Perspectives

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 64

Special Issue Editor


E-Mail Website
Guest Editor
Division of General Medicine, Department of Internal Medicine, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi, Tokyo 173-8610, Japan
Interests: lipid metabolism; residual cardiovascular risk; small dense LDL; lipoprotein(a); endothelial dysfunction; oxidative stress; inflammation; coronary artery disease

Special Issue Information

Dear Colleagues,

Despite major advances in lipid-lowering therapy, coronary artery disease (CAD) continues to pose a substantial clinical burden. Accumulating evidence suggests that residual cardiovascular risk persists even after achieving guideline-recommended LDL-C levels, highlighting the importance of addressing other contributors such as small dense LDL, lipoprotein(a), endothelial dysfunction, and oxidative stress. This Special Issue aims to explore the current understanding and future directions in the management of CAD, with a particular focus on mechanisms beyond traditional lipid metrics. We welcome original research and comprehensive reviews covering novel biomarkers, lipid subfractions, vascular function, inflammation, and emerging therapeutic strategies for residual risk reduction in CAD.

Prof. Dr. Tadateru Takayama
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • coronary artery disease
  • lipid-lowering therapy
  • residual risk
  • small dense LDL
  • lipoprotein(a)
  • endothelial dysfunction
  • oxidative stress
  • inflammation
  • biomarkers
  • cardiovascular prevention

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop